公开(公告)号：US20090123456A1

公开(公告)日：2009-05-14

申请号：US11724605

申请日：2007-03-15

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： A61K39/395 ,  C07K16/28 ,  G01N33/53 ,  C12Q1/68 ,  A61K31/715

CPC分类号： A61K31/46 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  G01N33/6863 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

摘要翻译： 一种治疗患有胰腺炎的患者的方法，其包括以足以减少从巨噬细胞释放的促炎细胞因子的量的治疗有效量的对α7烟碱受体选择性的胆碱能激动剂治疗所述患者，其中所述病症是 急性胰腺炎。 本发明的化合物包括可卡因的四元类似物; （1-氮杂 - 双环[2.2.2]辛-3-基） - 氨基甲酸1-（2-氟苯基） - 乙酯; 式（I）化合物，式（II）化合物，式（III）化合物，式（IV）化合物和能够减弱急性胰腺炎症状的寡核苷酸或模拟物，其中寡核苷酸或模拟物 基本上由大于5个核苷酸长的序列组成，其与α7胆碱能受体的mRNA互补。 本文描述了式（I），（II），（III）和（IV）的变量。

公开(公告)号：US07273872B2

公开(公告)日：2007-09-25

申请号：US10729427

申请日：2003-12-05

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： A01N43/42

CPC分类号： G01N33/6863 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  A61K31/46 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor.

摘要翻译： 提供了用于抑制患者中炎性细胞因子级联的方法。 该方法涉及用足以抑制炎性细胞因子级联的量的胆碱能激动剂治疗患者，其中胆碱能激动剂对α7烟碱受体具有选择性。

公开(公告)号：US07785808B2

公开(公告)日：2010-08-31

申请号：US11724605

申请日：2007-03-15

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： G01N33/567 ,  G01N33/53

CPC分类号： A61K31/46 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  G01N33/6863 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

摘要翻译： 一种治疗患有胰腺炎的患者的方法，其包括以足以减少从巨噬细胞释放的促炎细胞因子的量的治疗有效量的对α7烟碱受体选择性的胆碱能激动剂治疗所述患者，其中所述病症是 急性胰腺炎。 本发明的化合物包括可卡因的四元类似物; （1-氮杂 - 双环[2.2.2]辛-3-基） - 氨基甲酸1-（2-氟苯基） - 乙酯; 式（I）化合物，式（II）化合物，式（III）化合物，式（IV）化合物和能够减弱急性胰腺炎症状的寡核苷酸或模拟物，其中寡核苷酸或模拟物 基本上由大于5个核苷酸长的序列组成，它与α7胆碱能受体的mRNA互补。 本文描述了式（I），（II），（III）和（IV）的变量。

公开(公告)号：US20100256341A1

公开(公告)日：2010-10-07

申请号：US12818347

申请日：2010-06-18

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： C07K16/00

CPC分类号： A61K31/46 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  G01N33/6863 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

摘要翻译： 一种治疗患有胰腺炎的患者的方法，其包括以足以减少从巨噬细胞释放的促炎细胞因子的量的治疗有效量的对α7烟碱受体选择性的胆碱能激动剂治疗所述患者，其中所述病症是 急性胰腺炎。 本发明的化合物包括可卡因的四元类似物; （1-氮杂 - 双环[2.2.2]辛-3-基） - 氨基甲酸1-（2-氟苯基） - 乙酯; 式（I）化合物，式（II）化合物，式（III）化合物，式（IV）化合物和能够减弱急性胰腺炎症状的寡核苷酸或模拟物，其中寡核苷酸或模拟物 基本上由大于5个核苷酸长的序列组成，它与α7胆碱能受体的mRNA互补。 本文描述了式（I），（II），（III）和（IV）的变量。

公开(公告)号：US20110166148A1

公开(公告)日：2011-07-07

申请号：US12724888

申请日：2010-03-16

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： A61K31/4985 ,  A61K31/438 ,  A61K31/444 ,  A61K31/439 ,  A61K31/505 ,  A61K31/46 ,  A61P1/18

CPC分类号： A61K31/46 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  G01N33/6863 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

摘要翻译： 一种治疗患有胰腺炎的患者的方法，其包括以足以减少从巨噬细胞释放的促炎细胞因子的量的治疗有效量的对α7烟碱受体选择性的胆碱能激动剂治疗所述患者，其中所述病症是 急性胰腺炎。 本发明的化合物包括可卡因的四元类似物; （1-氮杂 - 双环[2.2.2]辛-3-基） - 氨基甲酸1-（2-氟苯基） - 乙酯; 式（I）化合物，式（II）化合物，式（III）化合物，式（IV）化合物和能够减弱急性胰腺炎症状的寡核苷酸或模拟物，其中寡核苷酸或模拟物 基本上由大于5个核苷酸长的序列组成，它与α7胆碱能受体的mRNA互补。 本文描述了式（I），（II），（III）和（IV）的变量。

公开(公告)号：US07238715B2

公开(公告)日：2007-07-03

申请号：US10957426

申请日：2004-09-30

申请人： Kevin J. Tracey ,  Hong Wang

发明人： Kevin J. Tracey ,  Hong Wang

IPC分类号： A01N43/40

CPC分类号： A61K31/46 ,  A61K31/00 ,  A61K31/439 ,  A61K31/444 ,  G01N33/6863 ,  G01N33/9406 ,  G01N2333/525 ,  G01N2333/54 ,  Y02A50/385 ,  Y02A50/411

摘要： A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein

摘要翻译： 一种治疗患有胰腺炎的患者的方法，其包括以足以减少从巨噬细胞释放的促炎细胞因子的量的治疗有效量的对α7烟碱受体选择性的胆碱能激动剂治疗所述患者，其中所述病症是 急性胰腺炎。 本发明的化合物包括可卡因的四元类似物; （1-氮杂 - 双环[2.2.2]辛-3-基） - 氨基甲酸1-（2-氟苯基） - 乙酯; 式（I）化合物，式（II）化合物，式（III）化合物，式（IV）化合物和能够减弱急性胰腺炎症状的寡核苷酸或模拟物，其中寡核苷酸或模拟物 基本上由大于5个核苷酸长的序列组成，其与α7胆碱能受体的mRNA互补。 本文描述了式（I），（II），（III）和（IV）的变量

公开(公告)号：US10420166B2

公开(公告)日：2019-09-17

申请号：US13542247

申请日：2012-07-05

申请人： Lixiang Xu ,  Hong Wang ,  Huarui Liang

发明人： Lixiang Xu ,  Hong Wang ,  Huarui Liang

IPC分类号： H04W76/30 ,  H04W8/08 ,  H04W36/00

摘要： Methods for avoiding handover failure are provided. The method includes determining, by a source Base Station (BS), to perform a handover of a User Equipment (UE); determining, by the source BS, whether a target BS connects with a user plane node serving the UE at the source BS; and releasing resources, when the target BS does not connect with the user plane node serving the UE at the source BS.

公开(公告)号：US10089263B2

公开(公告)日：2018-10-02

申请号：US15118501

申请日：2014-03-24

申请人： INTEL CORPORATION ,  Thiam Wah Loh ,  Gautham N. Chinya ,  Per Hammarlund ,  Reza Fortas ,  Hong Wang ,  Huajin Sun

发明人： Thiam Wah Loh ,  Gautham N. Chinya ,  Per Hammarlund ,  Reza Fortas ,  Hong Wang ,  Huajin Sun

IPC分类号： G06F13/24

摘要： A processor is disclosed and includes at least one core including a first core, and interrupt delay logic. The interrupt delay logic is to receive a first interrupt at a first time and delay the first interrupt from being processed by a first time delay that begins at the first time, unless the first interrupt is pending at a second time when a second interrupt is processed by the first core. If the first interrupt is pending at the second time, the interrupt delay logic is to indicate to the first core to begin to process the first interrupt prior to completion of the first time delay. Other embodiments are disclosed and claimed.

公开(公告)号：US20180225118A1

公开(公告)日：2018-08-09

申请号：US15943614

申请日：2018-04-02

申请人： Ed Grochowski ,  Hong Wang ,  John P. Shen ,  Perry H. Wang ,  Jamison D. Collins ,  James Held ,  Partha Kundu ,  Raya Leviathan ,  Tin-Fook Ngai

发明人： Ed Grochowski ,  Hong Wang ,  John P. Shen ,  Perry H. Wang ,  Jamison D. Collins ,  James Held ,  Partha Kundu ,  Raya Leviathan ,  Tin-Fook Ngai

IPC分类号： G06F9/30 ,  G06F9/38

CPC分类号： G06F9/30003 ,  G06F9/30087 ,  G06F9/3009 ,  G06F9/30101 ,  G06F9/3013 ,  G06F9/384 ,  G06F9/3851

摘要： A method and system to provide user-level multithreading are disclosed. The method according to the present techniques comprises receiving programming instructions to execute one or more shared resource threads (shreds) via an instruction set architecture (ISA). One or more instruction pointers are configured via the ISA; and the one or more shreds are executed simultaneously with a microprocessor, wherein the microprocessor includes multiple instruction sequencers.

公开(公告)号：US09867157B2

公开(公告)日：2018-01-09

申请号：US12527328

申请日：2008-02-13

申请人： Bing Bu ,  Xiaoqiang Li ,  Chunying Sun ,  Hong Wang ,  Lixiang Xu ,  Yanmin Zhu

发明人： Bing Bu ,  Xiaoqiang Li ,  Chunying Sun ,  Hong Wang ,  Lixiang Xu ,  Yanmin Zhu

IPC分类号： H04W60/06 ,  H04W76/06

CPC分类号： H04W60/06 ,  H04W76/32

摘要： A method for detachment of a mobile set within the equivalent route area moving between the communication systems comprising steps of: during the detachment process is implemented between a mobile set and a service node in one communication system, the service node generates one or more messages and transmits it to the service nodes in one or more communication system within the ERA. If the message is transmitted to the service node within the ERA of only one communication system, this service node transmits this message or the message generated according to this message to the service nodes within the ERA of the other communication system. With the method proposed in present invention, when a mobile is detached from two or more communication systems which share the same ERA, the service nodes in all communication systems within the ERA can still correctly manage the relevant information on this mobile set.